Slow and steady uptake of genAI in APAC healthcare in 2024


Generative AI has been well-received in the healthcare industry, offering potential for efficiency and improvement in patient care. Japanese partners are interested in using genAI platforms, while in the US, adoption is slower due to insurance and reimbursement considerations. Regulatory and cultural barriers will also impact adoption, with privacy and patient rights being major concerns. The success of genAI will depend on real-world outcomes, proven accuracy, and the ability to replicate or exceed human benchmarks. Developers need a deep understanding of the technology and healthcare, and change management will be crucial for user acceptance. GenAI has potential to bring value in clinical trials, documentation, patient interactions, and data analysis.

Source link

error: Content is protected !!